Conference
CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC.
Authors
Hellmann MD; Gettinger SN; Goldman JW; Brahmer JR; Borghaei H; Chow LQ; Ready N; Gerber DE; Juergens RA; Shepherd FA
Volume
34
Pagination
pp. 3001-3001
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2016
DOI
10.1200/jco.2016.34.15_suppl.3001
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X